Patent ID: 9127279
Filing Date: 2015-09-08
Classification: A61P,C07K,C12N,C12Y

Abstract:
1. A method for treating an infection by a strain of a human immunodeficiency virus (HIV) that is resistant to raltegravir or elvitegravir, wherein the method comprises administering to the subject in need thereof, a therapeutically effective amount of an miRNA selected from the group consisting of hsa-miR-18a (SEQ ID NO:2), hsa-miR-92a-1 (SEQ ID NO:3), hsa-miR-185* (SEQ ID NO:4), hsa-miR-219-1-3p (SEQ ID NO:5), hsa-miR-370 (SEQ ID NO:6), hsa-miR-518c* (SEQ ID NO:7), hsa-miR-595 (SEQ ID NO:8), hsa-miR-613 (SEQ ID NO:9), hsa-miR-939 (SEQ ID NO:10), hsa-miR-1228* (SEQ ID NO:11), hsa-miR-1231 (SEQ ID NO:12) and hsa-miR-1909 (SEQ ID NO:13) or combinations thereof.